Merck Keynote MK3475-671

A Phase III, Randomized, Double-blind Trial of Platinum Doublet Chemotherapy +/- Pembrolizumab (MK-3475) as Neoadjuvant/Adjuvant Therapy for Participants with Resectable IIB or IIIA Non-small Cell Lung Cancer
Contact phone
517.364.2835
Principal investigator
Gordan Srkalovic MD, PhD
Trial Category
Cancer
Trial SubCategory
Lung
Webform